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Introduction: Angiogenic factors, such as placental growth factor (PlGF) and soluble Flt-1 (sFlt-1), are key
regulators of placental vascular development. Evidence from in vitro studies indicates that fatty acids can
affect angiogenesis. We investigated the associations of maternal ﬁsh consumption and fatty acids levels
with angiogenic factors during pregnancy, and in cord blood in a large population-based prospective
cohort.
Methods: First trimester ﬁsh consumption was assessed among 3134 pregnant women using a food-
frequency questionnaire. Plasma fatty acid levels were measured in second trimester. Plasma PlGF and
sFlt-1 were measured in ﬁrst and second trimester and in cord blood. Associations of ﬁsh consumption or
fatty acid levels with angiogenic factors were assessed by multivariable linear regression analyses.
Results: There were no consistent associations of total ﬁsh or lean ﬁsh consumption with levels of PlGF,
sFlt-1, or sFlt-1/PlGF ratio. Neither fatty ﬁsh nor shellﬁsh were associated with angiogenic factors. Plasma
omega-3 polyunsaturated fatty acids, which are the main type of fatty acids in ﬁsh, were inconsistently
associated with angiogenic factors in second trimester and cord blood. Yet, higher levels of arachidonic
acid, an omega-6 polyunsaturated fatty acid, were associated with lower levels of PlGF and sFlt-1.
Discussion: We found no consistent associations of ﬁsh consumption or fatty acids levels with angiogenic
factors in a population with low ﬁsh consumption. Studies including populations with higher ﬁsh con-
sumption are required to fully grasp the potential effects of maternal ﬁsh consumption on placental
angiogenesis.
© 2015 Elsevier Ltd. All rights reserved.1. Introduction
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co).angiogenic factors [1]. Well known proangiogenic proteins are
Vascular Endothelial Growth Factor (VEGF) and Placental Growth
Factor (PlGF). These proangiogenic factors might promote placental
development by binding to its transmembrane receptor Flt-1,
thereby inducing gene expression to promote proliferation and
migration of trophoblasts [2,3]. A soluble variant of Flt-1, sFlt-1,
binds to circulating proangiogenic factors with high afﬁnity, thus
diminishing PlGF and VEGF availability for the transmembrane Flt-
1 receptor and inhibiting its proangiogenic signal [4,5]. Hence, sFlt-
1 has an antiangiogenic effect. An imbalance between the levels of
proangiogenic and antiangiogenic factors has been associated with
pregnancy complications such as preeclampsia and intra-uterine
growth restriction [5e7]. Additionally, plasma levels of PlGF and
Fig. 1. Flow chart of participants included for analyses.
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cohort [8]. As a measure of antiangiogenesis the sFlt-1/PlGF ratio
could be used [9].
Multiple environmental factors are known to affect placental
angiogenesis, including smoking, diabetes and maternal diet
[10e12]. Maternal diet is also known to inﬂuence blood pressure in
pregnancy and foetal outcomes as has been suggested in cohort and
caseecontrol studies [13e15]. Among other nutritional exposures,
higher ﬁsh consumption before and during pregnancy has been
associated with higher birth weight and lower risk of foetal growth
retardation in two European observational studies [16,17], although
this associationwas not found in our cohort [18]. Potential effects of
ﬁsh may be mediated through polyunsaturated fatty acids (PUFAs),
in particular omega-3 PUFAs. Omega-3 PUFA supplementation
during pregnancy has been shown to increase pregnancy duration,
head circumference and birth weight [19,20]. Evidence from in vitro
studies indicates that some PUFAs stimulated angiogenesis in a cell
line of ﬁrst trimester human trophoblasts potentially by increasing
the expression of angiogenic factors [21,22].
So far, no studies have evaluated the association between
maternal dietary intake of foods high in PUFAs, such as ﬁsh, and
human placental angiogenesis. Therefore, we investigated the as-
sociation of maternal ﬁsh consumption with the angiogenic factors
PlGF and sFlt-1 measured in the ﬁrst and second trimester, and in
cord blood. In addition, we evaluated the association of maternal
plasma fatty acids levels in second trimester with PlGF and sFlt-1
levels in the second trimester and in cord blood in a large
population-based birth cohort.
2. Methods
2.1. Study design and population
The present study was embedded in the Generation R Study, a
population-based prospective cohort study from foetal life onwards
in the city of Rotterdam, the Netherlands. Details of the study have
been described before [23]. All participants provided written
informed consent. The studywas carried out in accordancewith the
World Medical Association Declaration of Helsinki and approved by
the medical ethics committee of the Erasmus University Medical
Center, Rotterdam, the Netherlands.
For this particular study, we included only Dutch women,
because the food-frequency questionnaire (FFQ) was designed to
evaluate a Dutch diet. Of the total of 4546 participating Dutch
women, we excluded those enrolled after the 25th week of gesta-
tion (n ¼ 515), with missing information on ﬁsh consumption
(n ¼ 846), multiple pregnancies (n ¼ 1), unlikely total daily energy
intake (n ¼ 4) and those in whom no data on any of the angiogenic
factors at any time point were available (n ¼ 46), leaving 3134
women in our analyses (Fig. 1).
2.2. Fish intake
Maternal dietary intake, including fish consumption, was eval-
uated at enrolment (median 13.2 (95% range 9.9e21.6) weeks of
gestation) using a self-administered semi-quantitative FFQ adapted
from the validated FFQ of Klipstein-Grobusch et al. [24]. This FFQ
measured food intake over the prior three months, and covered
dietary intake during the ﬁrst trimester of pregnancy. The FFQ
considered consumption frequency, portion sizes [25], preparation
method and additions. To calculate average daily nutritional values,
the 2006 version of the Dutch food composition tablewas used [26].
Fish consumption (in grams per week) was assessed for total ﬁsh
intake and for speciﬁc types of ﬁsh [18]. Fish consumption was
groupedbased on thenutrient content into: leanﬁsh (codﬁsh, plaice,catﬁsh, sole ﬁsh, tuna, whiting and haddock), fatty ﬁsh (salmon,
herring, mackerel, eel, sardines, halibut, bloater, trout, anchovy and
gurnard) and shellﬁsh (crab, lobster, shrimps and mussels). Pro-
cessed ﬁsh, roe and ﬁsh derived from liver were not used in this
analyses. Total ﬁsh includes all the types of ﬁsh consumed.
2.3. Blood sampling
Peripheral venous blood samples were drawn during the visits
to the research centre in the ﬁrst (median 12.9 weeks (95% range
9.8e17.3)) and second trimester (median 20.4 weeks (95% range
18.6e22.9)). Umbilical venous cord blood samples were obtained
by midwives and obstetricians immediately after delivery (median
gestational age at delivery 40.3 weeks (95% range 36.0e42.3)). All
blood samples were transported to the regional laboratory,
centrifuged and the plasma distributed into 250mL aliquots and
stored at 80 C [27].
2.4. Fatty acid levels
The analysis of plasma glycerophospholipid FA compositionwas
performed on plasma samples derived during second trimester of
pregnancy in the Division of Metabolic Diseases and Nutritional
Medicine, Dr. von Hauner Children's Hospital, Ludwig-
Table 1
Characteristics of participants (n ¼ 3134)a.
Maternal characteristics Mean ± SD or median (95% range)
Age (years) 31.4 ± 4.3b
Gestational age at enrolment (weeks) 13.2 (9.9e21.6)b








Smoking during pregnancy, % (n)
Yes 28.5 (894)
No 71.5 (2240)
Alcohol use during pregnancy, % (n)
Yes 67.2 (2105)
No 32.8 (1029)
Folic acid supplementation use, % (n)
Yes 89.0 (2789)
No 11.0 (345)











Total daily energy intake (kJ/day) 8972 ± 2127b,c
Total ﬁsh intake (gram/week)d 75 (0e318)b
Lean ﬁsh intake (gram/week)d 24 (0e149)b
Fatty ﬁsh intake (gram/week)d 30 (0e150)b
Shellﬁsh intake (gram/week)d 0 (0e34.5)b
Plasma fatty acids
Docosahexaenoic acid (mg/L) 80.1 ± 20.0
Eicosapentaenoic acid (mg/L) 13.0 ± 4.2
Alpha-Linolenic acid (mg/L) 5.5 ± 1.8
Linoleic acid (mg/L) 352.3 ± 59.5
Arachidonic acid (mg/L) 154.5 ± 31.2
Omega-3/omega-6 ratio 0.2 ± 0.05
EPA/AA ratio 0.06 ± 0.04
DHA/AA ratio 0.5 ± 0.14
Angiogenic factors levels
First trimester
PlGF (pg/mL) 37.8 (14.4e154.7)
sFlt-1 (ng/mL) 4.9 (1.9e12.8)
sFlt-1/PlGF ratio 0.13 (0.02e0.43)
Second trimester
PlGF (pg/mL) 185.9 (73.2e569.3)
sFlt-1 (ng/mL) 4.7 (1.5e16.0)
sFlt-1/PlGF ratio 0.02 (0.01e0.11)
Cord blood
PlGF (pg/mL) 8.6 (0.0e20.7)
sFlt-1 (ng/mL) 0.45 (0.08e4.01)





Gestational age at birth (weeks) 40.3 (36.0e42.4)
Birth weight (grams) 3497 ± 550
a Values are mean ± SD when normally distributed or median (95% range) when
not normally distributed for continuous variables and percentages (n) for categor-
ical outcomes. The number of missings were 0.4% (n ¼ 14) for BMI at enrolment,
0.2% (n ¼ 7) for parity, 0.6% (n ¼ 19) for maternal education, 7.0% (n ¼ 219) for
smoking, 7.6% (n ¼ 238) for alcohol use, 17.6% (n ¼ 552) for folic acid supplemen-
tation use, 1.8% (n¼ 56) for pregnancy-induced hypertension, 5.2% (n ¼ 164) for
preeclampsia, 0.03% (n ¼ 1) for season of conception, 13.9% (n ¼ 435) for plasma
fatty acids, 0.03% (n¼ 1) for child sex, 0.03% (n¼ 1) gestational age at birth and 0.2%
(n ¼ 5) for birth weight. AA: Arachidonic acid, DHA: Docosahexanoic acid, EPA:
Eicosapentanoic acid, PlGF: Placental growth factor, sFlt-1: Soluble Flt-1.
b No missings.
c Value corresponds to a daily energy intake of 2143 ± 508 kcal/day.
d Absolute values of ﬁsh consumption.Maximilians-University of Munich following the high-throughput
method described by Glaser et al. [28]. The average coefﬁcient of
variation was 15.7%. Plasma FA concentration reﬂects only current
nutritional status.
Plasma PUFA levels are a result of both dietary intake and
metabolism. Plasma omega-3 and omega-6 PUFAs may compete in
these metabolic processes because the same rate-limiting en-
zymes are needed [29]. Therefore, we did not only take into ac-
count omega-3 PUFAs but also evaluated the associations with
omega-6 PUFAs which are derived from other dietary sources
than ﬁsh.
For the analyses, we used relative concentrations of the in-
dividual FAs as weight percentage of the total sum of FAs (%)
instead of absolute concentrations (mg/L), because fatty acid
levels are not only a reﬂection of dietary intake but also of
metabolism, the complex interplay between individual fatty
acids, and multiple additional factors[30]. The analysed omega-3
PUFAs were docosahexaenoic acid (DHA), eicosapentaenoic acid
(EPA) and alpha-linolenic acid (ALA). The analysed omega-6
PUFAs were linoleic acid (LA) and arachidonic acid (AA). Also
omega-3/omega-6, EPA/AA and DHA/AA ratios were evaluated.
The omega-3/omega-6 ratio was calculated by the sum of ﬁve
omega-3 PUFAs (ALA, eicosatreionic acid, EPA, docasapentaenoic
acid and DHA) divided by the sum the omega-6 PUFAs matching
the carbon chain length of the omega-3 PUFAs (LA, dihomo-
gamma-linolenic acid, AA, adrenic acid and osbond acid). The
EPA/AA and DHA/AA ratios have been used as cardiovascular risk
biomarkers [31].
2.5. Angiogenic factors
Levels of sFlt-1 and PlGF were measured in ﬁrst and second
trimester plasma and cord blood plasma at the Department of
Clinical Chemistry of the Erasmus UniversityMedical Center using a
two-step chemi-luminescent microparticle immunoassay (CMIA)
on the Architect System (Abbot Diagnostics B.V., Hoofddorp, the
Netherlands). Cord blood plasma, originating from the foetal cir-
culation, was evaluated in addition to maternal plasma because
studies have suggested a discordant release of sFlt-1 into both
circulations [32]. Plasma levels of sFlt-1 and PlGF were evaluated
individually and additionally combined within the sFlt-1/PlGF ratio,
which can be used as a measure of antiangiogenesis [9]. The
between-run coefﬁcients of variation for plasma sFlt-1 were 2.8% at
5.5 ng/mL and 2.3% at 34.0 ng/mL; and 4.7% at 24 pg/mL, and 3.8% at
113 pg/mL for plasma PlGF. The highest detected level was 150 ng/
mL for sFlt-1 and 1500 pg/mL for PlGF [7].
2.6. Covariates
Information on maternal age, folic acid supplementation, parity
and educational level was obtained from questionnaires completed
by the mothers at enrolment. Information on smoking and alcohol
consumption was obtained from questionnaires in each trimester.
As season of conception might inﬂuence maternal ﬁsh consump-
tion we back-calculated the month of conception from the gesta-
tional age and then categorized it into seasons: winter (December
to February), spring (March to May), summer (June to August) and
fall (September to November).
Maternal height and weight were measured at enrolment to
calculate BMI (kg/m2) (correlation coefﬁcient with pre-pregnancy
BMI 0.96). Gestational age at delivery, birth weight, foetal sex and
pregnancy complications (pregnancy-induced hypertension and
preeclampsia) were obtained frommedical records. The occurrence
of pregnancy complications was cross-validated using medical re-
cord review [7].
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We adjusted ﬁsh consumption for total energy intake to reduce
measurement error, to control for confounding and to evaluate the
effect of ﬁsh consumption independent of energy intake using the
nutrient residual method [33]. Energy-adjusted ﬁsh consumption
was derived by ﬁrst regressing ﬁsh consumption on total energy
intake, saving the residuals from this regression and then adding
the median ﬁsh consumption to these residuals. This gave us an
energy-adjusted ﬁsh intake for all women [33].
Subsequently, to reduce the inﬂuence of outlying data points,
ﬁsh consumption was divided in categories. The energy-adjusted
total ﬁsh consumption was grouped into ﬁve categories (0; 1e69;
70e139; 140e209; and >210 g per week), lean ﬁsh and fatty ﬁsh
consumption into four categories each (0; 1e34; 35e69; and >70 g
per week), and shellﬁsh consumption into three categories (0;
1e13; >14 g per week) as previously described [18]. The category of
“no ﬁsh consumption” was considered the reference category. The
plasma levels of sFlt-1 and PlGF as well as the sFlt-1/PlGF ratio were
natural logarithm (ln)-transformed to obtain a normal distribution.
We studied the association of maternal ﬁsh consumption with
levels of angiogenic factors and the association of plasma FA levels
with angiogenic factors using multivariable linear regression
models.
Each of the following variables were evaluated as potential
confounders in univariable models: age, parity, BMI, smoking,
educational level, foetal sex, season of conception and energy
intake. All these variables yielded a change of at least 5% in the
effect estimate andwere therefore included in the adjustedmodels.
Tests for trend were done by including the ﬁsh consumption cat-
egories as a continuous variable in the linear regression models. A
sensitivity analysis was performed in women without known dia-
betes mellitus or gestational diabetes (n ¼ 2771) because these
women may have received dietary advice which altered their di-
etary intake and additionally levels of angiogenic factors may differ
[34].Table 2
Associations between weekly maternal total ﬁsh consumption and levels of angiogenic f
Total ﬁsh consumption (energy-adjusted g/week) First trimester
n Beta 95% CI
Ln-PlGF pg/mL (n ¼ 2515)
0 155 Reference
1e69 935 0.028 0.105, 0.04
70e139 849 0.008 0.086, 0.06
140e209 416 0.007 0.090, 0.07
>210 160 0.015 0.113, 0.08
P for trend 0.61
Ln-sFlt-1 ng/mL (n ¼ 2513)
0 155 Reference
1e69 936 0.114y 0.025, 0.203
70e139 846 0.064 0.025, 0.15
140e209 415 0.092 0.004, 0.18
>210 161 0.059 0.055, 0.17
P for trend 0.74
Ln-sFlt-1/PlGF ratio (n ¼ 2505)
0 155 Reference
1e69 932 0.142y 0.034, 0.250
70e139 845 0.070 0.039, 0.17
140e209 414 0.099 0.018, 0.21
>210 159 0.063 0.075, 0.20
P for trend 0.44
Results from multivariable linear regression model, based on imputed data. P for trend w
regression model. The statistically signiﬁcant values are presented in bold (P-value <0.0
yP < 0.05, *P < 0.01.
Abbreviations: CI: conﬁdence interval, n: number of participants, PlGF: placental growth
a Adjusted for total energy intake, maternal age, gestational age at measurement, B
conception.Missing values for the covariates included in the regression
models (0.4% for BMI, 0.2% for parity, 0.6% for educational level and
7% for smoking) were imputed using multiple imputation [35]. Five
datasets were created and analysed independently and then the
results were pooled. All analyses were performed using both the
original data set and the imputed data sets. As the effect estimates
were very similar, we present only the pooled effect estimates with
their 95% conﬁdence intervals.
All statistical analyses were performed using SPSS Statistics
version 20 for Windows (PASW Inc., Chicago, IL, USA). P-values of
<0.05 were considered statistically signiﬁcant.
3. Results
Maternal and child characteristics are presented in Table 1
(Characteristics after imputations are presented in Supplementary
table 1). Median total ﬁsh intake was 75 g/week (95% range
0e318), mainly of fatty ﬁsh and lean ﬁsh consumption.
3.1. Fish intake and angiogenic factors
Associations of energy-adjusted total ﬁsh intake and angiogenic
factors are presented in Table 2. We found no association of
maternal energy-adjusted total ﬁsh intakewith PlGF levels at any of
the three time points. The association of total ﬁsh intakewith sFlt-1
levels was inconsistent. In the ﬁrst trimester, women with a total
ﬁsh intake of 1e69 g per week had 0.11 (95%CI 0.03, 0.20) ng/mL
higher Ln-sFlt-1 levels than women who did not consume ﬁsh.
However, the other categories of total ﬁsh intake were not associ-
ated with sFlt-1. In the second trimester, total ﬁsh intake was
associated with higher sFlt-1 levels in all categories, although not
statistically signiﬁcant in the highest category which may be due to
the lower number of women in this category (n ¼ 196) than in the
other categories (between 470 and 1063 women). We found no
doseeresponse relation and no association was found in cord
blood.actorsa.
Second trimester Cord blood
n Beta 95% CI n Beta 95% CI
Ln-PlGF pg/mL (n ¼ 2845) Ln-PlGF pg/mL (n ¼ 1552)
181 Reference 108 Reference
9 1063 0.017 0.094, 0.060 560 0.090 0.464, 0.284
9 934 0.002 0.080, 0.076 508 0.006 0.195, 0.206
7 470 0.007 0.091, 0.077 255 0.069 0.349, 0.487
4 197 0.044 0.141, 0.053 121 0.156 0.402, 0.090
0.73 0.79
Ln-sFlt-1 ng/mL (n ¼ 2844) Ln-sFlt-1 ng/mL (n ¼ 1695)
181 Reference 111 Reference
1063 0.157* 0.060, 0.255 613 0.129 0.095, 0.353
2 934 0.106y 0.007, 0.204 552 0.098 0.128, 0.325
9 470 0.141* 0.035, 0.247 294 0.124 0.118, 0.365
3 196 0.108 0.015, 0.232 125 0.279 0.002, 0.559
0.78 0.18
Ln-sFlt-1/PlGF ratio (n ¼ 2844) Ln-sFlt-1/PlGF ratio (n ¼ 1469)
181 Reference 102 Reference
1063 0.175* 0.059, 0.290 522 0.159 0.055, 0.372
8 934 0.108 0.009, 0.225 487 0.152 0.063, 0.366
6 470 0.148y 0.023, 0.273 245 0.192 0.039, 0.423
1 196 0.151y 0.006, 0.297 113 0.266y 0.001, 0.532
0.65 0.10
as conducted by including ﬁsh consumption categories in the multivariable linear
5). The P for trend values are presented in italics.
factor, sFlt-1: soluble Flt-1.
MI at enrolment, foetal sex, parity, maternal education, smoking, and season of
Table 3
Associations between maternal fatty acid plasma levels and levels of angiogenic factorsa.
Fatty acids (weighed percentage) Second trimester Cord blood
Beta 95% CI Beta 95% CI
Ln-PlGF pg/mL (n ¼ 2699) Ln-PlGF pg/mL (n ¼ 1311)
DHA (22:6n-3) 0.006 0.024, 0.011 0.012 0.089, 0.113
EPA (20:5n-3) ¡0.062y ¡0.116, ¡0.007 0.077 0.397, 0.243
ALA (18:3n-3) 0.158 0.026, 0.342 0.853 0.268, 1.973
LA (18:2n-6) 0.007 0.001, 0.014 0.015 0.055, 0.025
AA (20:4n-6) ¡0.022* ¡0.035, ¡0.009 0.029 0.093, 0.035
n-3/n-6 ratio 0.157 0.542, 0.227 1.003 1.266, 3.271
EPA/AA ratio 0.285 0.754, 0.183 0.146 2.893, 2.601
DHA/AA ratio 0.087 0.049, 0.223 0.341 0.429, 1.112
Ln-sFlt-1 ng/mL (n ¼ 2699) Ln-sFlt-1 ng/mL (n ¼ 1444)
DHA (22:6n-3) 0.011 0.032, 0.011 0.051 0.106, 0.005
EPA (20:5n-3) 0.044 0.112, 0.025 0.055 0.127, 0.236
ALA (18:3n-3) 0.066 0.166, 0.298 0.676y 0.068, 1.284
LA (18:2n-6) 0.001 0.010, 0.008 0.005 0.017, 0.027
AA (20:4n-6) ¡0.022* ¡0.038, ¡0.007 ¡0.044y ¡0.084, ¡0.005
n-3/n-6 ratio 0.021 0.505, 0.463 0.211 1.466, 1.044
EPA/AA ratio 0.129 0.718, 0.461 1.001 0.548, 2.550
DHA/AA ratio 0.074 0.095, 0.243 0.029 0.396, 0.455
Ln-sFlt-1/PlGF ratio (n ¼ 2699) Ln-sFlt-1/PlGF ratio (n ¼ 1238)
DHA (22:6n-3) 0.005 0.031, 0.022 0.023 0.077, 0.032
EPA (20:5n-3) 0.018 0.065, 0.101 0.086 0.088, 0.261
ALA (18:3n-3) 0.092 0.372, 0.187 0.564 0.031, 1.159
LA (18:2n-6) 0.008 0.019, 0.003 0.008 0.029, 0.014
AA (20:4n-6) 0.000 0.020, 0.019 0.032 0.071, 0.007
n-3/n-6 ratio 0.136 0.447, 0.719 0.324 0.901, 1.549
EPA/AA ratio 0.157 0.553, 0.867 1.043 0.432, 2.518
DHA/AA ratio 0.013 0.219, 0.192 0.071 0.342, 0.484
Results from multivariable linear regression model, based on imputed data. The statistically signiﬁcant values are presented in bold (P-value <0.05).
yP < 0.05, *P < 0.01.
Abbreviations: AA: arachidonic acid, ALA: alpha-linolenic acid, CI: conﬁdence interval, DHA: docosahexanoic acid, EPA: eicosapentanoic acid, LA: linoneic acid, n: number of
participants, n-3/n-6: omega-3/omega-6 ratio, PlGF: placental growth factor, sFlt-1: soluble Flt-1.
a Adjusted for total energy intake, maternal age, gestational age at measurement, BMI at enrolment, foetal sex, parity, maternal education and smoking.
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were also inconsistent. In the ﬁrst trimester, an energy-adjusted
intake of 1e69 g per week of total ﬁsh intake, but none of the
other categories, was associated with an increased ratio. In the
second trimester total ﬁsh intake was associated with increased
ratios in all categories except for 70e139 g per week, but there was
no doseeresponse relation.
The association of lean ﬁsh consumption with levels of PlGF,
sFlt-1 and the sFlt-1/PlGF ratio is presented in Supplementary table
2. There were some scattered signiﬁcant associations for single
categories of intake of lean ﬁsh, but no clear pattern could be
distinguished. Neither fatty ﬁsh nor shellﬁsh intake were associ-
ated with angiogenic factors (Supplementary tables 3 and 4).
Restricting the analyses to women without diabetes resulted in a
minor attenuation of the effect estimates (data not shown).
3.2. Plasma fatty acids and angiogenic factors
Of the omega-3 PUFAs, higher levels of EPAwere associatedwith
low PlGF levels in the second trimester and higher levels of ALA
were associated with increased sFlt-1 levels in cord blood (Table 3).
Higher levels of the omega-6 PUFA arachidonic acid were associ-
ated with signiﬁcantly lower PlGF and sFlt-1 levels in the second
trimester and with lower sFlt-1 levels in cord blood. We found no
associations of any of the fatty acid ratio's with PlGF or sFlt-1.
4. Discussion
We found no consistent associations of ﬁrst trimester maternal
ﬁsh consumptionwith levels of the proangiogenic factor PlGF or the
anti-angiogenic factor sFlt-1. Higher total ﬁsh intake increased sFlt-1 levels in some categories of intake, but there was not a dos-
eeresponse effect. The association of ﬁsh consumption with the
sFlt-1/PlGF ratio showed a similar pattern to that for sFlt-1. When
we evaluated the effect of the plasma FA levels on angiogenesis,
higher EPA was associated with lower PlGF levels in second
trimester and ALA was associated with higher sFlt-1 levels in cord
blood. Higher arachidonic acid was associated with lower sFlt-1
levels in both measurements and in second trimester PlGF levels.
Altered levels of pro-angiogenic and anti-angiogenic factors
have been associated with adverse pregnancy outcomes, including
preeclampsia and foetal growth restriction [6,7].
Maternal overall diet has been found to inﬂuence foetal growth
[14], also consumption of food items such as ﬁsh has been associ-
ated with foetal growth in some studies [16,17,36]. Similarly, results
from a systematic review have indicated that supplementation of
omega-3 PUFAs resulted in lower prevalence of preterm birth and
higher birthweight [20], although these results were not conﬁrmed
in another systematic review [19]. Results from several in vitro and
animal studies, mostly in the ﬁeld of cancer research, have sug-
gested that food or food-derived compounds, such as components
of cinnamon or grape seed, may inﬂuence angiogenesis [37,38].
However, whether maternal ﬁsh intake, or the intake of ﬁsh-
derived compounds, is associated with markers of human
placental angiogenesis has not yet been studied, to the best of our
knowledge.
Our results suggest a potential anti-angiogenic effect of total ﬁsh
intake in the second trimester reﬂected in the increased sFlt-1
levels and sFlt-1/PlGF ratio. In this association, the absence of a
signiﬁcant p-value for trend may not preclude the possibility of a
threshold effect rather than a doseeresponse association [39].
Arachidonic acid (AA), an omega-6 PUFA, was signiﬁcantly
P.K. Bautista Ni~no et al. / Placenta 36 (2015) 1178e1184 1183associated with lower levels of both PlGF and sFlt-1, however ﬁsh is
not a source of AA. Two omega-3 PUFAs EPA and ALA were
associated with anti-angiogenesis, EPA through lower PlGF levels
in second trimester and ALA through higher sFlt-1 levels in cord
blood. These ﬁndings are in agreement with the effect of PUFAs on
angiogenesis in cancer cell lines where omega-3 PUFAs, such as
EPA, exert anti-inﬂammatory and antineoplastic effects, whereas
omega-6 PUFAs, such as AA, promote inﬂammation and carcino-
genesis [40,41]. In addition, omega-3 PUFAs were found to down-
regulate the production of VEGF and thus inhibit angiogenesis in
human tumours implanted in mice and rats. However, EPA, DHA
and AA increased angiogenesis in ﬁrst trimester trophoblast cells
[22] and Basak et al. [21] reported that these PUFAs also increased
the expression of COX-2 gene, which may be associated with in-
duction of angiogenesis. However, EPA, DHA and AA increased
angiogenesis in ﬁrst trimester trophoblast cells [22] and Basak et al.
[21] reported that these PUFAs also increased the expression of
COX-2 gene, which may be associated with induction of
angiogenesis.
Although the mechanisms underlying the different effects of
PUFAs in cancer cells and in trophoblasts remain to be established,
distinct fatty acids metabolism could be expected in different cell
lines, because differences in the handling of fatty acids have been
shown between ﬁrst trimester trophoblasts and third trimester
trophoblasts [21]. In our study, the increase in sFlt-1 levels, secreted
by trophoblasts [42], may be explained by increased trophoblastic
volume rather than anti-angiogenesis, which would be beneﬁcial.
Unfortunately, we were not able to evaluate the role of trophoblast
or trophoblastic volume in the association of ﬁsh consumptionwith
angiogenic factors, because this information was not collected in
our participants. Our ﬁnding that AA was associated with both
proangiogenic and antiangiogenic factors during pregnancy needs
further study whether AA in pregnancy may indeed be involved in
both processes.
Besides the intake of fatty acids, an important aspect of ﬁsh
consumption is the bioaccumulation of polychlorinated biphenyls
(PCBs) and dioxins. Foetal exposure to PCBs and dioxins increases
the risk for intra-uterine growth retardation, leads to changes in
thyroid hormone metabolism, immunosuppression and neurolog-
ical deﬁcits [17,36,43]. Also, plasma PCB levels have been associated
with lower syncytiotrophoblast volume and increased PlGF levels
in pregnant women [44]. It is possible that potential beneﬁcial ef-
fects of PUFAs on placental angiogenesis might be counterbalanced
by the effects of PCBs or other substances contained in ﬁsh. Also,
interactions of the components of ﬁsh with other dietary and
metabolic factors, as well as the effects of the preparation method
of the ﬁsh are yet to be explored.
Our study has several strengths, including its large sample size,
the population-based design, the in-depth information about ﬁsh
intake and the extensive information on a large number of potential
confounders. However, the study also has limitations. Our study
population had a low ﬁsh consumption. The median total ﬁsh
intake was 75 g (half a serving) per week and only 7% of pregnant
women consumed more than 210 g of ﬁsh per week which was
lower than the mean total ﬁsh intake in the general Dutch popu-
lation of 88e104 g per week [45]. Also, total ﬁsh intake in the
Netherlands was the lowest in a study across 10 European countries
[45]. Therefore, wewere likely limited in our ability to study the full
effects of ﬁsh intake, mainly due to a low variation in ﬁsh con-
sumption between the subjects especially in subgroups of speciﬁc
types of ﬁsh. Also, the exact amount of ﬁsh intake measured by an
FFQ might not be very precise. However, it does permit adequate
ranking of participants by intake, as participants with a high intake
will also report a higher intake of ﬁsh than those with a low intake
[46]. Also, as mentioned above, there may be further aspects to ﬁshintake beyond fatty acids that also inﬂuence levels of angiogenic
factors and clinical outcomes that we were not able to take into
account. Lastly, we got some scattered signiﬁcant results. As we
performed a large number of statistical tests, some signiﬁcant re-
sults might arise by chance (multiple testing). However, our sig-
niﬁcant results were clustered within the second trimester and in
two speciﬁc (and related) outcomes, sowe feel that multiple testing
is unlikely to explain all our ﬁndings.
In a population with low ﬁsh consumption, we found no
consistent associations of total ﬁsh or speciﬁc groups of ﬁsh con-
sumption with PlGF and sFlt-1 levels or the sFlt-1/PlGF ratio. These
associations need further evaluation in studies including pop-
ulations with a higher ﬁsh intake, and taking into account other
components of ﬁsh intake, method of preparation and further di-
etary components to fully grasp the potential effects of maternal
ﬁsh intake on placental angiogenesis.Contribution to authorship
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